PROTEOMICS INTERNATIONAL LABORATORIES LTD(PIQ)

The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted immediately, following the release by PIQ of an announcement regarding an application for regulatory approval of the PromarkerD test in Australia and the reimbursement payment rate for the PromarkerD test in the United States.

Centers for Medicare & Medicaid Services list PromarkerD predictive test for diabetic kidney disease and assign payment rate of US$390.75 in the United States. CMS is the single largest payer for health care in the United States, with Medicare and Medicaid collectively responsible for 42 per cent of healthcare spending and providing health coverage to more than 100 million Americans. The Australian Therapeutic Goods Administration advises decision not to include the PromarkerD test in the Australian Register of Therapeutic Goods due primarily to change of manufacturer. TGA decision does not affect Proteomics International's activities in its primary markets of the United States and Europe. Approximately 32 million adults live with diabetes in the United States and 61 million in Europe, as compared to 1.5 million in Australia.

The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the reimbursement payment rate for the PromarkerD test in the United States and the application for regulatory approval of the PromarkerD test in Australia. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Monday, 2 October 2023.

The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the application for regulatory approval of the PromarkerD test in Australia and the reimbursement payment rate for the PromarkerD test in the United States. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Monday, 25 September 2023.

The securities of Proteomics International Laboratories Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of an announcement regarding an application for regulatory approval of the PromarkerD test in Australia and the reimbursement payment rate for the PromarkerD test in the United States.

The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted immediately following the release by PIQ of an announcement regarding the licensing of the PromarkerD test in the US market.

Proteomics International and Sonic Healthcare USA sign binding and exclusive Letter of Intent regarding an exclusive licence for PromarkerD in the United States. Estimated 32 million people or eleven per cent of the American population live with diabetes - testing these patients with PromarkerD could help identify their risk of developing diabetic kidney disease.

The securities of Proteomics International Laboratories Ltd ("˜PIQ') will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of an announcement.

The suspension of trading in the securities of Proteomics International Laboratories Ltd will be lifted from the commencement of trading on Monday, 5 July 2021, following the release by PIQ of an announcement regarding a presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021.

Proteomics International Laboratories Ltd refers to its ASX release of 25 June 2021 titled "Modelling shows PromarkerD could save US payers $384 billion". Following consultation with ASX, and to ensure the findings from the study are not interpreted as forecast financial information under ASIC Regulatory Guide 170, Proteomics International has agreed to retract that Announcement. In retracting that Announcement, Proteomics International notes that investors should not rely on the information as a basis for making an investment decision about its shares. Importantly, shares in Proteomics International have not traded since release of the Announcement. The economic health benefit study was undertaken to support the Company's application for a unique reimbursement code for PromarkerD in the US, and was conducted by independent consultant, Boston Healthcare Associates.

The Company requests an extension to the voluntary suspension of its securities pending the release of an announcement regarding the presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021. The Company estimates that it will be able to lodge an announcement on or before the commencement of trading on Tuesday, 6 July 2021.

The securities of Proteomics International Laboratories Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of PIQ, pending the release of the presentation given at the American Diabetes Association's 81st Scientific Sessions, 25-29 June 2021.

listed entity carried for record purposes only